GST in Pharmaceutical Industry: Rates, ITC & Compliance

The Indian pharmaceutical industry occupies a critical nexus in the global healthcare supply chain, serving as a foundational pillar for both domestic public health and international medical accessibility.

Universally recognised as the "pharmacy of the world", India represents the third-largest pharmaceutical market globally by volume and the eleventh by value, commanding domestic turnover exceeding USD 66.02 billion in 2024 and projected to reach USD 145.09 billion by 2032, expanding at a compound annual growth rate (CAGR) of 10.48 per cent.

As the predominant supplier of generic medications, the sector fulfils approximately 20 per cent of the global generic demand, supplying over 50 per cent of Africa’s generics, nearly 40 per cent of the generic demand in the United States, and approximately 25 per cent of all medicines distributed in the United Kingdom.

The industry is supported by a vast infrastructure encompassing over 10,500 manufacturing units and 60,000 generic brands across various therapeutic areas, creating direct and indirect employment for approximately 2.7 million individuals.

The sector's scale is reflected in the market capitalisation of its leading entities. As of mid-2024, the industry apex is dominated by major conglomerates, demonstrating the immense capital density of the sector.

Rank	Corporate Entry	Market Capitlisation (Approximate, May)
1	Sun Pharma	₹366,456 crore (US $38 billion)
2	Cipla	₹113,515 crore (US $12 billion)
3	Dr. Reddy's Laboratories	₹103,161 crore (US $11 billion)
4	Divi's Laboratories	₹100,366 crore (US $10 billion)
5	Zydus Lifesciences	₹97,958 crore (US $10 billion)

The transition to the Goods and Services Tax (GST) regime on July 1, 2017, conceptualised initially in 1999, marked the most profound fiscal paradigm shift for this sector since the liberalisation of the Indian economy.

Prior to GST, pharmaceutical manufacturers navigated a labyrinthine tax structure comprising Central Excise Duty (typically 12.5%, though manufacturers in excise-free zones like Baddi and Paonta Sahib in Himachal Pradesh enjoyed a concessional rate of 1.5%), Value Added Tax (VAT) averaging 5%, and Central Sales Tax (CST) at 2% for inter-state transactions, alongside entry taxes and octroi.

This fragmented architecture required maintaining multiple state-wise depots, often referred to as carrying and forwarding agencies, merely to circumvent CST levies, leading to highly inefficient, tax-driven supply chains rather than operationally optimised distribution networks.

The introduction of the GST subsumed these disparate levies into a unified, destination-based consumption tax. By enabling seamless input tax credit (ITC) flows across state borders, the GST framework incentivised the consolidation of fragmented warehouses into optimised hub-and-spoke distribution models, fundamentally reducing logistics and transaction costs, thereby acting as an economic catalyst for the sector.

Empirical studies indicate that the removal of the cascading tax effect often referred to as a "tax on tax" has streamlined operations and fostered robust growth, particularly in the realm of medical tourism, which has expanded manifold due to the standardised cost of healthcare services and pharmaceutical procurement.

However, the transition has not been entirely frictionless. Empirical analyses assessing the pre- and post-GST impact reveal a dichotomy in adaptation between large, organised corporate entities and unorganised, rural retailers.
Surveys conducted across key metropolitan and tier-two cities, such as Chennai and Lucknow, demonstrate that while organised urban retailers quickly adopted digital compliance mechanisms, smaller rural pharmacies faced major hurdles in digital literacy, accounting support, and compliance costs. 

Furthermore, as the GST law matured, a myriad of complex challenges emerged. The pharmaceutical sector, characterised by heavy research and development (R&D) outlays, strict regulatory pricing controls under the Drugs (Prices Control) Order (DPCO), mandatory product expiries, and complex international trade structures, found itself grappling with unintended legislative frictions.

This thesis provides an exhaustive, multidimensional analysis of the structural, judicial, and economic dynamics of the GST regime as applied to the Indian pharmaceutical sector, evaluating the impacts of recent legislative amendments, judicial pronouncements, and the intersection of tax policy with overarching healthcare economics.

Taxonomic rationalisation and the economics of healthcare delivery

The classification and rate structure of pharmaceutical products under the GST regime reflects a delicate macroeconomic balancing act between generating vital state revenue and ensuring the affordability of essential healthcare

Unlike the singular Revenue Neutral Rate (RNR) envisioned early in the GST discourse, which policymakers ultimately deemed too rigid to accommodate the diverse socioeconomic realities of the Indian populace, practical necessities dictated a multi-tiered slab structure comprising 5%, 12%, 18%, and 28% brackets.

Categorisation and rate slabs

Pharmaceutical products and medical devices are primarily categorised under Chapter 30 and Chapter 90 of the Harmonised System of Nomenclature (HSN). The GST Council has historically maintained a segmented classification for the sector, which was further rationalised following the landmark 53rd, 54th, and 55th GST Council meetings to address prevailing market anomalies and align with global health imperatives.

Category	Representative HSN Codes	GST Rate	Representative Products / Healthcare Interventions
Exempt / Nil Rated	Various	0%	Human blood, contraceptives, specific life-saving drugs, individual health insurance premiums (effective September), hearing aids, and healthcare services by clinical establishments.
Merit Rate	3003,3004, 9021	5%	Essential life-saving drugs, FSSAI-compliant diabetic foods, vaccines, Ayurvedic/Unani/Siddha/homoeopathic medicaments, orthopaedic/cardiac/dental implants, targeted cancer drugs (e.g., Trastuzumab Deruxtecan, Osimertinib, and Durvalumab), and wheelchairs.
Standard Rate (Lower)	9018, 3005, 3006	12%	Standard chemical formulations, branded synthetic drugs, surgical instruments (scalpels, forceps), syringes, needles, absorbable sutures, bandages, and blood collection bags.
Standard Rate (Upper)	9027, 9018, 9402	18%	Diagnostic equipment (MRI, CT, and X-ray machines), laboratory equipment (blood analysers, centrifuges, and PCR machines), hospital furniture (ICU beds and examination tables), and multi-parameter patient monitors.

Economic implications of rate restructuring

Recent policy shifts orchestrated by the GST Council underscore a definitive transition toward a health-positive tax regime.

The reduction of the GST rate on critical oncology therapeutics such as Trastuzumab Deruxtecan and Osimertinib from 12% to 5% directly lowers the out-of-pocket expenditure for patients managing catastrophic illnesses, aligning fiscal policy with the objectives of the Ayushman Bharat initiative.

Similarly, the reduction of GST on job-work services for pharmaceutical manufacturing (including formulations, API processing, and packaging) from 12% to 5% harmonises the service tax input rate with the output rate of essential medicines, mitigating localised instances of working capital blockages caused by credit accumulation.

However, the dichotomy in the taxation of medical devices remains a persistent point of friction within healthcare economics. While life-sustaining implants such as coronary stents, pacemakers, and orthopaedic plates are taxed at a concessional 5%, capital-intensive diagnostic and surgical equipment, including MRI machines, RT-PCR thermocyclers, and operating theatre lights, are taxed at an 18% rate.

Because healthcare services provided by doctors, hospitals, and diagnostic centres remain exempt from GST, these institutions operate outside the GST credit chain. Consequently, they are statutorily barred from claiming ITC on the 18% tax paid on these capital goods.

From a microeconomic perspective, this unrecoverable tax morphs into a sunk cost, which is invariably passed on to the patient through higher diagnostic fees and procedural charges, thereby diluting the overarching governmental objective of affordable healthcare.

International comparative analysis

Contextualising India's GST framework against international consumption tax architectures reveals divergent strategies in balancing healthcare funding and patient accessibility. An analysis of Value Added Tax (VAT) systems in the European Union (EU) and the United Kingdom (UK) demonstrates specialised mechanisms designed to insulate the healthcare sector from indirect tax burdens.

The UK, which allocates approximately 9% of its healthcare budget to medicines, one of the lowest proportions internationally, applies a zero-rate VAT to dispensed prescriptions, ensuring that the ultimate consumer bears no indirect tax burden on essential pharmaceuticals.

Similarly, several EU member states implement extensive VAT exemptions or highly reduced rates specifically targeted at defined therapeutic categories, acting as a protective mechanism for public health expenditure.

Recent geopolitical and economic realignments, particularly the negotiation of Free Trade Agreements (FTAs) between India, the UK, and the EU, are expected to redraw the contours of the pharmaceutical and medtech landscapes.

These agreements aim to reduce compliance frictions and harmonise regulatory standards, which, when coupled with India's domestic GST rationalisation, are projected to significantly bolster the competitiveness of Indian pharmaceutical formulations and medical device exports in highly regulated European markets.

The inverted duty structure (IDS) paradox and Rule 89(5) dynamics

One of the most significant structural anomalies affecting India's pharmaceutical manufacturing sector is the Inverted Duty Structure (IDS). This phenomenon occurs when the GST rate on raw materials, packaging, and input services exceeds the GST rate on the finished output, leading to a structural accumulation of unutilised ITC.

The mechanism of capital blockage

In the pharmaceutical value chain, the procurement profile is highly complex. Active Pharmaceutical Ingredients (APIs), critical excipients, industrial chemical inputs (such as sulphuric acid and caustic soda), and sophisticated packaging materials (including laminates, specialised tags, and corrugated cartons) frequently attract an 18% GST rate.

Conversely, the finished formulations are predominantly taxed at 12% or the concessional 5% rate. This structural asymmetry results in a continuous, compounding accumulation of unutilised ITC in the manufacturer's electronic credit ledger, effectively trapping vital working capital that could otherwise be deployed toward capacity expansion or R&D.

Section 54(3) of the Central Goods and Services Tax (CGST) Act, 2017, provides the statutory mechanism for the refund of this accumulated credit. However, Rule 89(5) of the CGST Rules strictly governs the exact computation and eligibility criteria for this refund, a provision that has been the epicentre of intense legislative amendment and judicial scrutiny over the past several years.

The VKC Footsteps precedent and formulaic evolution

The original architecture of Rule 89(5) sparked immense controversy, as it permitted the refund of ITC accumulated on "inputs" (physical goods) but expressly excluded "input services" and "capital goods".

Pharmaceutical entities which incur massive input service expenditures related to global clinical trials, regulatory consulting (e.g., REACH compliance, environmental impact assessments), logistics, and contract research argued that this exclusion violated the foundational seamless credit ethos of the GST regime.

The ensuing jurisprudence culminated in the Supreme Court of India's landmark judgement in Union of India v. VKC Footsteps India Pvt. Ltd., which upheld the legislative competence of the government to restrict IDS refunds exclusively to input goods.

The Court unequivocally ruled that if the legislature had intended to provide refunds for both goods and services under an inverted structure, it would not have explicitly restricted the scope by utilising the specific term "inputs" in the proviso to Section 54(3).

Following this definitive judicial pronouncement, the CBIC, via Notification No. /-Central Tax (effective July 5, 2022), introduced a revised mathematical formula under Rule 89(5) to prevent input service credit from artificially inflating the refund claim while ensuring a more equitable attribution of output tax. The revised formula is expressed as follows:

Maximum Refund Amount = {(Turnover of inverted rated supply of goods and services Net ITC) / Adjusted Total Turnover} - {Tax payable on such inverted rated supply of goods and services (Net ITC / ITC availed on inputs and input services)}

Crucially, "Net ITC" in the numerator is strictly restricted to the credit availed on input goods only, expressly excluding input services and capital goods.

Operational repercussions on biopharma and speciality chemicals

The prospective application of this amended formula effectively codified a permanent, recurring reduction in the refund quantum for R&D-heavy speciality pharmaceutical, biopharmaceutical, and chemical manufacturers.

For instance, a speciality formulator running a highly complex input mix comprising external analytical laboratories, clinical trial retainers, and capital-heavy plant equipment amortisation faces a permanent reduction in refund realisations of about 30 to 40 per cent compared to the pre-amendment notional base.

To navigate this, pharmaceutical companies must now execute meticulous, audit-grade manual or automated reconciliations to segregate their GSTR-2B ledgers into distinct buckets for input goods, input services, and capital goods.

If a manufacturer accidentally bleeds input-service ITC (e.g., freight services, plant maintenance contracts, or regulatory consulting) into the Net ITC numerator, it triggers immediate deficiency memos (Form GST RFD-03), partial rejections by the proper officer, and severe penalty exposures under Section 74 of the CGST Act.

Consequently, the unrefunded ITC on input services acts as a silent, unrecoverable tax on pharmaceutical innovation, marginally eroding the global cost-competitiveness of India's complex generics and biosimilars pipelines.

Export frameworks, advance authorisations, and the demise of Rule 96(10)

The Indian pharmaceutical industry is heavily export-orientated, acting as a primary engine for the nation's foreign exchange earnings. In the financial year 2024-25, pharmaceutical exports touched ₹245,962 crore, dwarfing imports, which stood at ₹63,573 crore.

Under GST jurisprudence, exports are legally classified as "zero-rated supplies" pursuant to Section 16 of the Integrated Goods and Services Tax (IGST) Act, ensuring that exported goods do not export domestic taxes.

Exporters have traditionally utilised two primary procedural routes: exporting under a Letter of Undertaking (LUT) or bond without the payment of tax and subsequently claiming a refund of accumulated unutilised ITC (governed by Rule 89), or exporting on payment of IGST and claiming an automated, system-driven refund from Customs upon the successful filing of the Export General Manifest (EGM) (governed by Rule 96).

The Rule 96(10) conundrum and the "double benefit" theory

For decades, the pharmaceutical sector utilised the Advance Authorisation scheme under Chapter 4 of the Foreign Trade Policy (FTP) to import critical APIs and Key Starting Materials (KSMs) duty-free, provided they were physically incorporated into the final export product.

However, Rule 96(10) of the CGST Rules stipulated a highly restrictive and controversial condition: if a manufacturer availed the benefit of specified customs duty exemptions (such as Notification 78/2017-Customs for Export Orientated Units or 79/2017-Customs for Advance Authorisations) on imported inputs, they were statutorily prohibited from utilising the Route 2 mechanism (exporting the finished formulations upon payment of IGST to claim an automated refund).

Revenue designed this provision to prevent a perceived "double benefit" of availing duty-free imports while simultaneously encashing accumulated ITC through IGST refunds. In practice, however, it resulted in massive administrative chaos and severe liquidity crunches. Exporters who inadvertently exported on payment of IGST after utilising Advance Authorisations faced draconian show-cause notices demanding the immediate surrender of the refunded IGST, augmented by exorbitant interest and penalties.

Judicial extinguishment and the Council meeting resolution

Recognising the disproportionate hardship inflicted on the export sector, which fundamentally contradicted the ease-of-doing-business mandate, the GST Council Meeting recommended the outright omission of Rule 96(10), alongside sub-rules 89(4A) and 89(4B). This pivotal omission was codified via Notification No. 20/2024-Central Tax, coming into effect in October 2024.

Crucially, the legal mechanics of this omission generated immediate and consequential appellate jurisprudence. Because the government omitted the rule without inserting a specific savings clause to protect pending departmental actions, high courts rapidly intervened regarding ongoing litigation.

In landmark rulings such as Techno Waxchem (P.) Ltd. v. Union of India before the Calcutta High Court and Hikal Limited before the Bombay High Court, the judiciary held that relying on Section 6 of the General Clauses Act 1897, which preserves pending proceedings upon the repeal of an enactment, is impermissible for subordinate legislation such as the CGST Rules.

Consequently, the courts decreed that the omission of Rule 96(10) obliterates the rule from the statute book as if it never existed for pending proceedings.

All show-cause notices, investigations, and demands pending adjudication that were solely predicated on Rule 96(10) violations automatically abated and lapsed. This jurisprudential development secured a monumental victory for pharmaceutical exporters, unlocking massive amounts of previously disputed capital and restoring certainty to export pricing models.

Intermediary taxation and the export of clinical research

The pharmaceutical sector's deep integration into global R&D pipelines relies heavily on Clinical Research Organisations (CROs), contract manufacturers (CDMOs), and marketing intermediaries situated in India but providing bespoke services to foreign principals.

Under standard destination-based consumption tax principles, a service consumed abroad by a foreign entity, paid for in convertible foreign exchange, qualifies unambiguously as an "export of service" and is thus zero-rated.

However, Section 13(8)(b) of the IGST Act imposes a controversial statutory fiction regarding "intermediary services".

It mandates that when an intermediary (an entity arranging or facilitating the supply of goods or services between two or more persons) is located in India, the "place of supply" is deemed to be the location of the supplier (India), regardless of the foreign principal's geographical location or the locus of ultimate consumption.

The Dharmendra M. Jani constitutional test

The constitutional validity of Section 13(8)(b) was fiercely contested, culminating in a highly scrutinised, fractured verdict by a Division Bench of the Bombay High Court, which was subsequently resolved by a third referee judge in the seminal case of Dharmendra M. Jani v. Union of India.

The petitioners, acting as marketing intermediaries for foreign entities, argued that taxing services inherently consumed outside India violates Article 286 and Article 269A of the Constitution, essentially imposing a local, origin-based tax on an export transaction, thereby restricting their fundamental right to carry on trade under Article 19(1)(g).

The Division Bench produced divergent views: Justice Ujjal Bhuyan opined that Section 13(8)(b) fell foul of the overall scheme of the GST architecture and was unconstitutional, whereas Justice Abhay Ahuja upheld its validity. The referee judge ultimately concurred with the latter, and the High Court upheld the constitutional validity of Section 13(8)(b) and Section 8(2) of the IGST Act.

The judiciary ruled that the creation of a legal fiction to determine the place of supply falls squarely within the legislative competence of Parliament. However, the Court provided a nuanced, critical caveat: this fiction is strictly confined to the IGST Act. It cannot be legally imported into the CGST or SGST Acts to classify the transaction as an intra-state supply liable to dual local taxes (CGST and SGST).

Therefore, Indian CROs and marketing agents facilitating drug trials, regulatory filings, or global distribution for foreign pharmaceutical parents must charge IGST on their service fees.

While this resolves the ambiguity regarding the type of tax to be levied, it effectively embeds a non-creditable tax cost into India's service export pricing, marginally eroding the global competitiveness of India's clinical research ecosystem compared to jurisdictions with pure zero-rating for all exported services.

Operational frictions: ITC reversals, expired goods, and free samples

Unlike durable goods, pharmaceutical products are governed by strict biological efficacy timelines that culminate in mandatory expiration dates. The Drugs and Cosmetics Act comprehensively mandates the withdrawal and safe destruction of expired formulations to protect public health. The GST treatment of these biological realities presents significant, ongoing compliance hurdles for manufacturers.

Sales returns vs. physical destruction

When a retailer or stockist returns expired medicines to the wholesaler or original manufacturer, the GST law provides two primary mechanisms for resolution. Under the first mechanism, the manufacturer may issue a credit note under Section 34(1) of the CGST Act, provided it is executed within the stipulated statutory time frame, thereby adjusting and reducing their outward tax liability for that period.

However, once the manufacturer takes possession of the expired stock and physically destroys it, Section 17(5)(h) of the CGST Act is unequivocally triggered. This section states that ITC shall not be available in respect of goods "lost, stolen, destroyed, written off or disposed of by way of gift or free samples".

The manufacturer must therefore calculate and reverse the ITC attributable to the raw materials, APIs, and packaging originally used to manufacture the now-destroyed batch.

This requirement has led to protracted litigation, with pharmaceutical companies arguing that destroying expired goods is a statutory mandate, not a voluntary write-off, and therefore should not trigger ITC reversal. Nonetheless, prevailing interpretations and circulars mandate strict adherence to Section 17(5)(h).

Physician samples and clinical trials

The pharmaceutical marketing model relies on distributing free physician samples to medical practitioners to familiarise them with efficacy and dosage profiles. Because these samples are distributed without any underlying consideration, they do not qualify as a "supply" under Section 7 of the CGST Act.

Consequently, as explicitly clarified by CBIC Circular 92/11/2019-GST and corroborated by subsequent advance rulings, the ITC availed on all inputs and input services utilised in manufacturing or procuring these free samples must be meticulously quantified and reversed under Section 17(5)(h).

This regulatory stance requires sophisticated ERP configurations to trace the exact input cost of non-commercial output batches separately from commercial production lines, adding significant administrative overhead to standard marketing operations.

Corporate overheads: The shift from cross-charge to mandatory ISD

The operational structure of large pharmaceutical corporations typically involves a centralised Head Office (HO) or corporate hub that procures common services such as SAP licensing, statutory audit fees, centralised legal counsel, brand management, and R&D overheads which directly benefit multiple manufacturing units and distribution depots registered across different states under the same PAN.

Historical ambiguity and the Columbia Asia precedent

Historically, the sector struggled with the severe dichotomy between utilising the Input Service Distributor (ISD) mechanism and the Cross-Charge mechanism.

In the highly disruptive Columbia Asia Hospitals Advance Ruling, the authority held that the activities of a corporate office (such as accounting, IT, and HR) benefiting branch offices constitute a taxable supply of services between "distinct persons" under Schedule I of the CGST Act, thereby necessitating a cross-charge invoice with the levy of applicable GST.

This interpretation led to prolonged, pan-India litigation until CBIC Circular 199/11/2023 clarified that businesses inherently had the option to distribute third-party service credits via either the ISD route or the cross-charge route, and that internally generated support services did not mandatorily require cross-charging if the recipient branch was eligible for full ITC.

The Finance Act 2024 mandate

To enforce strict auditability, transparency, and uniformity in how common credits are distributed, the Finance Act, 2024, fundamentally overhauled this paradigm by amending Section 2(61) and Section 20 of the CGST Act, effective April 1, 2025. The legislative amendment explicitly removed the optionality that previously existed: any office receiving tax invoices for common input services (including services liable to taxation under the Reverse Charge Mechanism, or RCM) must mandatorily register as an Input Service Distributor.

This paradigm transition requires pharmaceutical entities to rapidly undertake the following compliance measures:

1. Dedicated registration: Obtain dedicated ISD GSTINs (via Form REG-01) distinct from their normal operational registrations, even if operating from the same premises.
2. Compliance filing: File mandatory monthly GSTR-6 returns to document the receipt and distribution of the credit.
3. Pro-rata allocation: Allocate ITC strictly on a pro-rata basis driven by the comparative turnover of the respective branches utilising the service during the relevant period, as prescribed under Rule 39 of the CGST Rules.

Failure to comply with this framework after April 2025 constitutes a serious procedural violation. It exposes the manufacturer to allegations of wrongful credit retention at the Head Office, corresponding demands for interest under Section 50, and potential penalties under Section 74, necessitating immediate system upgrades across all major pharmaceutical IT architectures.

The valuation conundrum: Corporate guarantees under Rule 28(2)

Pharmaceutical conglomerates, particularly those engaged in capital-intensive expansions or global acquisitions, frequently utilise holding company structures to secure favourable credit terms for their subsidiaries, extending corporate guarantees to banking and financial institutions.

Historically, when the parent company charged no consideration or commission, taxpayers successfully argued that no taxable supply occurred.

Drawing upon Section 126 of the Indian Contract Act, 1872, businesses posited that a guarantee is merely a contingent contract that does not crystallise into a service until the principal debtor defaults, a stance validated in the pre-GST era by the Supreme Court in the Edelweiss Financial Services service tax ruling.

The 52nd GST Council upended this settled position, leading to the insertion of sub-rule (2) in Rule 28 of the CGST Rules via Notification 52/2023-Central Tax in October 2023. Leveraging the powers under Section 15(4) of the CGST Act, Rule 28(2) created a stringent deemed valuation mechanism.

It stipulated that the value of corporate guarantees provided to related parties shall be deemed to be 1% of the guarantee amount offered, or the actual consideration charged, whichever is higher. This mandated an 18% GST levy (under HSN 999799) on the deemed 1% value, fundamentally altering inter-corporate financing costs.

This rule faced immediate, widespread constitutional challenges across multiple High Courts. In the seminal ruling involving Torrent Power and associated entities, the Gujarat High Court delivered a highly nuanced judgement. The Court upheld the foundational legislative competence behind Rule 28(2) and Section 15(4), affirming that the government possessed the authority to prescribe valuation rules for related-party transactions.

However, the judiciary provided critical, multifaceted relief to the industry:

1. Retrospectivity struck down: The Court definitively ruled that the deemed valuation mechanism cannot be applied retrospectively to corporate guarantees executed prior to the rule's introduction on October 26, 2023. Consequently, past demands and coercive actions under Section 74 were quashed.
2. Reading down "whichever is higher": The Court found that the expression "whichever is higher" could lead to arbitrary, confiscatory results. To save the provision from constitutional infirmity under Article 14, the Court read down the phrase, cementing that the rule is purely a valuation mechanism, not an independent charging section.
3. Export exemption: Following intense industry representations, the CBIC further amended the rule in July 2024 (via Notification 12/2024-Central Tax) to explicitly clarify that Rule 28(2) does not apply when the subsidiary recipient is located outside India. This amendment protects outward foreign direct investments by Indian pharmaceutical multinationals, treating such transactions effectively as zero-rated exports.

Intersecting regulatory domains: Anti-profiteering (Section 171) and DPCO 2013

The pharmaceutical sector operates under a unique, dual-compliance matrix that is virtually unparalleled in other industries: meticulous tax compliance under the CGST Act combined with rigorous pricing compliance under the Essential Commodities Act, 1955, executed via the Drugs (Prices Control) Order, 2013 (DPCO 2013).

Section 171 and the transition to GSTAT

Section 171 of the CGST Act embodies the statutory anti-profiteering mandate, requiring any reduction in the tax rate or enhancement in ITC to be passed on to the recipient via a commensurate reduction in prices.

Although the National Anti-Profiteering Authority (NAA) and subsequently the Competition Commission of India (CCI) faced a statutory sunset on April 1, 2025 (meaning no new cases or complaints can be admitted under Section 171), the legacy of enforcement remains potent.

Jurisdiction to adjudicate pending appeals and enforce prior orders has shifted to the GST Appellate Tribunal (GSTAT) Principal Bench in New Delhi. Furthermore, future malfeasance regarding price manipulation falls under the ambit of the Consumer Protection Act, 2019, covering unfair trade practices.

Judicial precedents set by the Delhi High Court in cases such as Reckitt Benckiser and L'Oréal India strictly interpret the concept of "commensurate reduction". The courts held that Section 171 is a consumer-welfare measure addressing unjust enrichment.

Crucially, a supplier cannot offset GST rate reductions by employing alternative methodologies such as increasing grammage, offering post-sale discounts, or citing increased advertising expenditures; the Maximum Retail Price (MRP) must be explicitly and transparently lowered. Non-compliance attracts a severe penalty of 10% of the profiteered amount under Section 171(3A) of the CGST Act.

The NPPA and DPCO reconciliation

For pharmaceutical companies, the GST anti-profiteering mandate intersects violently with the regulatory architecture of the National Pharmaceutical Pricing Authority (NPPA). Under Paragraphs 4, 14, and 15 of DPCO 2013, the NPPA establishes rigid ceiling prices for scheduled formulations (e.g., vital anti-infectives, cardiovascular drugs, and anti-diabetics) based on market-share averages, exclusive of GST.

When the GST Council reduces a rate, such as the recent reduction of targeted cancer drugs from 12% to 5% in the 54th meeting, the manufacturer is thrust into a highly compressed operational timeline.

They are granted a fleeting 30-day window to recalibrate their ERP pricing masters, execute the physical relabelling or restickering of inventory across thousands of decentralised depot locations, and issue formal trade notifications to distributors.

If subsequent shelf-level retail audits detect any post-effective-date sales where the MRP remains above the revised GST-inclusive ceiling, the manufacturer is immediately liable for overcharging recovery under Paragraph 20 of DPCO 2013.

This recovery comprises the principal overcharged amount plus Wholesale Price Index (WPI) linked interest, quickly escalating into a massive, compounding liability documented under Form DPCO-6. The reconciliation of per-SKU MRPs against every NPPA notification thus represents a critical junction where tax compliance and pricing law converge.

Fiscal incentives and direct-indirect tax frictions: PLI vs. MAT

To counter severe, structural supply chain vulnerabilities exposed vividly during the pandemic when it became evident that nearly 70% of APIs and Key Starting Materials (KSMs) utilised by Indian facilities originated from China, the Government of India launched aggressive Production Linked Incentive (PLI) schemes.

The scheme for the pharmaceutical sector, backed by an outlay exceeding Rs 15,000 crore, aims to radically achieve import substitution and elevate India from an "assembler" of drugs to a true manufacturing powerhouse.

The scheme provides structured incentives based on global manufacturing revenue tiers (Group A for revenues > Rs 5,000 crore, Group B, and Group C) and offers incentive rates ranging from 10% to 6% on incremental sales of domestically manufactured critical APIs and complex generics.

However, this ambitious industrial policy frequently collides with direct taxation frameworks, creating a complex friction point. The PLI quarterly disbursements received by manufacturers are recognised as book income under Ind AS 20 (Accounting for Government Grants).

While intended purely as a capital subsidy to offset the high costs of establishing greenfield bulk-drug parks, these grants flow directly into the statement of profit and loss, significantly inflating the book profit for the financial year.

Consequently, under Section 115JB of the Income Tax Act, 1961, these grants are subjected to the Minimum Alternate Tax (MAT) at 15% (plus applicable surcharge and health-and-education cess), as there is no specific Explanation 1 deduction provided for PLI grants.

This creates a paradoxical fiscal scenario: a Tier-1 API manufacturer receives a government subsidy to foster domestic resilience and compress logistics costs, only to have a significant portion of that capital immediately reclaimed by the exchequer via MAT.

Pharmaceutical finance teams must therefore model highly complex, three-register tax-provisioning workbooks to meticulously track PLI grants, compute Section 115JB book profits, and manage Section 115JAA MAT credit carry-forwards (which remain valid for 15 assessment years) to accurately assess the net cash flow realisation of the government's incentive programme.

What does the GST framework mean for pharmaceutical companies?

GST has helped modernise pharmaceutical supply chains by replacing multiple indirect taxes, improving interstate credit flow and supporting more efficient distribution. At the same time, the sector continues to face complex issues involving inverted duty refunds, export procedures, ITC reversals, mandatory ISD compliance, corporate guarantees and regulated medicine pricing.

For pharmaceutical businesses, effective GST management therefore requires more than routine return filing. Finance and tax teams must closely align ITC, export, pricing and inter-branch processes with changing GST requirements. Masters India can support pharmaceutical companies with GST compliance software and APIs designed to simplify reconciliation, invoicing and tax workflows across complex operations.